These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 19100901

  • 1. Modern approaches to combining sirolimus with calcineurin inhibitors.
    Stevens RB.
    Transplant Proc; 2008 Dec; 40(10 Suppl):S21-4. PubMed ID: 19100901
    [Abstract] [Full Text] [Related]

  • 2. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report.
    Stevens RB, Mercer DF, Grant WJ, Freifeld AG, Lane JT, Groggel GC, Rigley TH, Nielsen KJ, Henning ME, Skorupa JY, Skorupa AJ, Christensen KA, Sandoz JP, Kellogg AM, Langnas AN, Wrenshall LE.
    Transplantation; 2008 May 27; 85(10):1391-9. PubMed ID: 18497677
    [Abstract] [Full Text] [Related]

  • 3. Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients.
    Klem P, Cooper JE, Weiss AS, Gralla J, Owen P, Chan L, Wiseman AC.
    Transplantation; 2009 Oct 15; 88(7):891-6. PubMed ID: 19935460
    [Abstract] [Full Text] [Related]

  • 4. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E, Aufricht C.
    Pediatr Transplant; 2006 Jun 15; 10(4):474-8. PubMed ID: 16712606
    [Abstract] [Full Text] [Related]

  • 5. A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes.
    Stevens RB, Foster KW, Miles CD, Lane JT, Kalil AC, Florescu DF, Sandoz JP, Rigley TH, Nielsen KJ, Skorupa JY, Kellogg AM, Malik T, Wrenshall LE.
    Transplantation; 2015 Jan 15; 99(1):197-209. PubMed ID: 25083614
    [Abstract] [Full Text] [Related]

  • 6. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A, Nart A, Taşli FA, Postaci H, Aykas A, Doğan M, Sahin T.
    Nephrology (Carlton); 2008 Feb 15; 13(1):80-6. PubMed ID: 18199109
    [Abstract] [Full Text] [Related]

  • 7. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML, Ahsan N, Wadei HM, Genco PV, Geiger XJ, Willingham DL, Taner CB, Hewitt WR, Grewal HP, Nguyen JH, Hughes CB, Gonwa TA.
    Transplantation; 2009 Jan 27; 87(2):227-32. PubMed ID: 19155977
    [Abstract] [Full Text] [Related]

  • 8. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
    Stevens RB, Foster KW, Miles CD, Kalil AC, Florescu DF, Sandoz JP, Rigley TH, Malik T, Wrenshall LE.
    PLoS One; 2015 Jan 27; 10(10):e0139247. PubMed ID: 26465152
    [Abstract] [Full Text] [Related]

  • 9. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 10. Low-dose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy.
    Laftavi MR, Patel S, Soliman MR, Alnimri M, Kohli R, Said M, Pankewycz O.
    Transplant Proc; 2011 Mar 27; 43(2):466-8. PubMed ID: 21440735
    [Abstract] [Full Text] [Related]

  • 11. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors.
    Bajjoka I, Hsaiky L, Brown K, Abouljoud M.
    Liver Transpl; 2008 Jan 27; 14(1):66-72. PubMed ID: 18161842
    [Abstract] [Full Text] [Related]

  • 12. Rabbit antithymocyte induction and dosing in deceased donor renal transplant recipients over 60 yr of age.
    Patel SJ, Knight RJ, Suki WN, Abdellatif A, Duhart BT, Krauss AG, Mannan S, Nezakatgoo N, Osama Gaber A.
    Clin Transplant; 2011 Jan 27; 25(3):E250-6. PubMed ID: 21231963
    [Abstract] [Full Text] [Related]

  • 13. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B.
    Transplant Rev (Orlando); 2009 Jan 27; 23(1):47-52. PubMed ID: 19027616
    [Abstract] [Full Text] [Related]

  • 14. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
    Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyó JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF, Rapamune Maintenance Regimen Study Group.
    Transpl Int; 2005 Jan 27; 18(1):22-8. PubMed ID: 15612979
    [Abstract] [Full Text] [Related]

  • 15. Single-dose rATG induction at renal transplantation: superior renal function and glucoregulation with less hypomagnesemia.
    Stevens RB, Lane JT, Boerner BP, Miles CD, Rigley TH, Sandoz JP, Nielsen KJ, Skorupa JY, Skorupa AJ, Kaplan B, Wrenshall LE.
    Clin Transplant; 2012 Jan 27; 26(1):123-32. PubMed ID: 21401720
    [Abstract] [Full Text] [Related]

  • 16. Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.
    Knight RJ, Kerman RH, McKissick E, Lawless A, Podder H, Katz S, Van Buren CT, Kahan BD.
    Clin Transplant; 2008 Jan 27; 22(5):645-50. PubMed ID: 18657156
    [Abstract] [Full Text] [Related]

  • 17. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
    Krüger B, Fischereder M, Jauch KW, Graeb C, Hoffmann U, Böger CA, Banas B, Obed A, Schlitt HJ, Krämer BK.
    Transplant Proc; 2007 Mar 27; 39(2):518-21. PubMed ID: 17362772
    [Abstract] [Full Text] [Related]

  • 18. Living related kidney transplantation without calcineurin inhibitors: initial experience in a Mexican center.
    Martinez-Mier G, Mendez-Lopez MT, Budar-Fernandez LF, Estrada-Oros J, Franco-Abaroa R, George-Micelli E, Rios-Martinez L, Mendez-Machado GF.
    Transplantation; 2006 Dec 15; 82(11):1533-6. PubMed ID: 17164728
    [Abstract] [Full Text] [Related]

  • 19. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 20. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes.
    Benavides CA, Pollard VB, Mauiyyedi S, Podder H, Knight R, Kahan BD.
    Transplantation; 2007 Jul 15; 84(1):83-8. PubMed ID: 17627242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.